SELLAS Life Sciences (SLS) Liabilities and Shareholders Equity (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $26.5 million as the latest value for Q3 2024.
- Quarterly Liabilities and Shareholders Equity rose 227.79% to $26.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $66.1 million through Dec 2024, up 6.59% year-over-year, with the annual reading at $6.2 million for FY2023, 70.31% down from the prior year.
- Liabilities and Shareholders Equity for Q3 2024 was $26.5 million at SELLAS Life Sciences, up from $15.1 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $46.0 million in Q4 2020, with the low at $6.2 million in Q4 2023.
- Average Liabilities and Shareholders Equity over 5 years is $24.9 million, with a median of $24.4 million recorded in 2024.
- The sharpest move saw Liabilities and Shareholders Equity plummeted 70.31% in 2023, then surged 227.79% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $46.0 million in 2020, then plummeted by 42.94% to $26.3 million in 2021, then dropped by 20.29% to $20.9 million in 2022, then tumbled by 70.31% to $6.2 million in 2023, then skyrocketed by 326.19% to $26.5 million in 2024.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $26.5 million, $15.1 million, and $24.4 million for Q3 2024, Q2 2024, and Q1 2024 respectively.